Regeneron Pharmaceuticals Inc
REGNRegeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious medical conditions. Founded in 1988, it specializes in monoclonal antibody technologies and has a broad pipeline targeting areas such as ophthalmology, oncology, immunology, and infectious diseases. Known for its collaborations and investment in scientific research, Regeneron has contributed significantly to the development of treatments for various diseases.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 4, 2026 | $0.94 | 2026-05-20 | 2026-05-20 |
| March 5, 2026 | $0.94 | 2026-02-20 | 2026-02-20 |
| December 5, 2025 | $0.88 | 2025-11-20 | 2025-11-20 |
| September 3, 2025 | $0.88 | 2025-08-18 | 2025-08-18 |
| June 6, 2025 | $0.88 | 2025-05-20 | 2025-05-20 |
Dividends Summary
- Consistent Payer: Regeneron Pharmaceuticals Inc has rewarded shareholders with 6 dividend payments over the past 1 years.
- Total Returned Value: Investors who held REGN shares during this period received a total of $5.40 per share in dividend income.
- Latest Payout: The most recent dividend of $0.94/share was paid 44 days ago, on June 4, 2026.
- Yield & Schedule: REGN currently pays dividends quarterly with an annual yield of 0.54%.
- Dividend Growth: Since 2025, the dividend payout has grown by 6.8%, from $0.88 to $0.94.
- Dividend Reliability: REGN has maintained or increased its dividend for 6 consecutive payments.
Company News
ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending...
Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR fra...
Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, cover...
